Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 629-637

  Tseng, Tai Chung ^a,b   Yu, Ming Lung ^c   Liu, Chun Jen ^b   Lin, Chih Lin ^d   Huang, Yi Wen ^e   Hsu, Ching Sheng ^a   Liu, Chen Hua ^b   Kuo, Stephanie Fang Tzu ^f   Pan, Corinna Jen Hui ^f   Yang, Sheng Shun ^g   Su, Chien Wei ^h   Chen, Pei Jer ^b   Chen, Ding Shinn ^b   Kao, Jia Horng ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; HLA DP ANTIGEN; HLA DPB1 ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BASAL CORE PROMOTER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC CORRELATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; TREATMENT DURATION; VIRUS LOAD; VIRUS TYPING;

EID: 84984539678     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1841     Document Type: Article

References (36)

1. Kao J.H., Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403.
2. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
3. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
4. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
5. Liaw Y.F., Lau G.K., Kao J.H., et al. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55:2727-2734.
6. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
7. Buster E.H., Hansen B.E., Lau G.K., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137:2002-2009.
8. Tseng T.C., Liu C.J., Wang C.C., et al. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009; 14:203-210.
9. Tseng T.C., Liu C.J., Wang C.C., et al. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 2008; 28:1034-1041.
10. Chotiyaputta W., Lok A.S. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009; 6:453-462.
11. Erhardt A., Reineke U., Blondin D., et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31:716-725. (Pubitemid 30118641)
12. Tangkijvanich P., Komolmit P., Mahachai V., et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46:117-123.
13. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
14. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
15. Rauch A., Kutalik Z., Descombes P., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
16. Kamatani Y., Wattanapokayakit S., Ochi H., et al. A genomewide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41:591-595.
17. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
18. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
19. Yeh S.H., Tsai C.Y., Kao J.H., et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41:659-666.
20. Liu C.J., Chen P.J., Lai M.Y., et al. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003; 124:80-90.
21. Wigginton J.E., Cutler D.J., Abecasis G.R. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76:887-893. (Pubitemid 40563110)
22. Barrett J.C., Fry B., Maller J., et al. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
23. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66:87-98. (Pubitemid 351482562)
24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
25. Kurosaki M., Enomoto N., Asahina Y., et al. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996; 49:115-123. (Pubitemid 26194267)
26. Okamoto H., Tsuda F., Akahane Y., et al. Hepatitis B virus with mutations in the core promoter for an e antigennegative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:8102-8110.
27. Buckwold V.E., Xu Z., Yen T.S., et al. Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. J Gen Virol 1997; 78:2055-2065. (Pubitemid 27367694)
28. Günther S., Piwon N., Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653)↗T, A(1762)↗T and G(1764)↗A mutations in the core promoter. J Gen Virol 1998; 79:375-380. (Pubitemid 28048443)
29. Baptista M., Kramvis A., Kew M.C. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology 1999; 29:946-953. (Pubitemid 29109614)
30. Moriyama K. Reduced antigen production by hepatitis B virus harbouring nucleotide deletions in the overlapping X gene and precore-core promoter. J Gen Virol 1997; 78:1479-1486. (Pubitemid 27281351)
31. Kao J.H., Wu N.H., Chen P.J., et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
32. Lin C.L., Kao J.H. To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B. Clin Infect Dis 2007; 44:1665-1666.
33. King J.K., Yeh S.H., Lin M.W., et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology 2002; 36:1416-1424. (Pubitemid 35403532)
34. Chen P.J., Lin C.G., Lin F.Y., et al. Genetic structural differences between responders and non-responders to interferon therapy for chronic hepatitis-B patients. J Hum Genet 2006; 51:984-991. (Pubitemid 44800744)
35. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79:3851-3854. (Pubitemid 40327973)
36. Lim S.G., Cheng Y., Guindon S., et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007; 133:951-958. (Pubitemid 47381357)